VERAXA Biotech to Trade on Nasdaq Following Merger

VERAXA Biotech AG, a biopharmaceutical company developing novel cancer therapies, announced the successful completion of its business combination with Voyager Acquisition Corp. The combined entity will begin trading on the Nasdaq Capital Market on June 11, 2026, under the ticker symbol VRXA.

The company specializes in developing next-generation cancer treatments, including bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). VERAXA's proprietary BiTAC platform is designed for precise targeting of cancer cells while sparing healthy tissue, aiming to improve both efficacy and safety.

VERAXA recently presented promising preclinical data at the American Association for Cancer Research (AACR) annual meeting. The data indicated that the BiTAC platform candidates performed as intended in vitro and in vivo, demonstrating a potential for an improved therapeutic index compared to traditional TCEs. The company's pipeline primarily focuses on solid tumors.

The business combination provides VERAXA with a strengthened financial position, including $27.5 million in senior secured notes and a $50 million share purchase agreement. These funds are intended to advance VERAXA's oncology drug candidates towards clinical development.

"Entering this next chapter as a public company with significant momentum is a transformational milestone for VERAXA," stated CEO Christoph Antz. "We look forward to fully unlocking the transformative therapeutic potential of our BiTAC-TCE and BiTAC-ADC programs and establishing our BiTAC platform as a launch pad for a multitude of innovative cancer therapies."